Ernexa Therapeutics Inc. Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Ernexa Therapeutics Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2020-12-31 was -$1.00K.
- Ernexa Therapeutics Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2020-09-30 was $0.00.
- Ernexa Therapeutics Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2020-06-30 was $0.00.
- Ernexa Therapeutics Inc. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2020-03-31 was $44.00K.
- Ernexa Therapeutics Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2020 was $43.00K.
- Ernexa Therapeutics Inc. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2017 was $209.00K.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 12 month |
|---|---|---|
| 2020-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $43.00K 10-K · filed 2021-03-11 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | |
| 2020-03-31 | $44.00K 10-Q · filed 2020-05-20 | |
| 2017-12-31 | $209.00K 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |